Patent Application
20250049952
Incorporated by reference in its entirety herein is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: One 165,079 Byte XML file named “766164.xml,” dated Dec. 29, 2022.
Propionic acidemia (PA) is a life-threatening autosomal recessive disorder of organic acid metabolism in humans with an estimated incidence of 1:250,000-1:750,000 births. It is caused by a deficiency of propionyl-CoA carboxylase (PCC), a ubiquitously expressed, heteropolymeric mitochondrial enzyme involved primarily in the catabolism of propiogenic amino acids, particularly isoleucine, valine, methionine, and threonine, as well as odd-chain fatty acids.
Most frequently, PA presents in the neonatal period with hyperammonemia, vomiting, poor feeding, and hypotonia and progresses into a life-threatening metabolic crisis. Patients who survive suffer from recurrent metabolic instability and can develop multisystemic complications, especially cardiomyopathy.
Over the decades, it has been repeatedly documented that PA patients with an early and severe clinical course experience increased mortality and disease associated morbidity (Surtees et al., Pediatr. Neurol., 8(5): 333-7 (1992); Shchelochkov et al., Propionic Acidemia, May 17, 2012 [updated Oct. 6, 2016]. In: GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021. PMID: 22593918).
The recalcitrant nature of the disorder to conventional medical management, including the dietary restriction of amino acid precursors, L-carnitine supplementation, and administration of metronidazole to reduce the generation of propionic acid by intestinal bacteria, has led to the implementation of elective liver transplantation (LT) as an experimental surgical treatment for PA.
While not curative of all aspects of the disorder, successful LT in the setting of PA provides restoration of metabolic stability and protection from early death, and therefore represents a clinical benchmark for gene replacement or addition approaches that might increase hepatic PCC expression and activity. Nevertheless, organ availability, surgical complications, and toxic side effects of life-long immunosuppression after LT, including the development of the post transplant lymphoproliferative disorder (PTLD), remain as practical constraints to the widespread adoption of LT as a preferred treatment for PA.
Accordingly, there exists a need for improved treatments for PA.
An aspect of the invention provides a polynucleotide expression cassette comprising: (a) a synthetic PCCA polynucleotide (synPCCA) selected from the group consisting of: (i) a polynucleotide comprising the nucleic acid sequence of any one of SEQ ID NOs: 2-7; and (ii) a polynucleotide comprising a nucleic acid sequence with at least 80% identity to the nucleic acid sequence of any one of SEQ ID NOs: 2-7 which encodes the polypeptide of SEQ ID NO:8 and has equivalent or greater expression in a host relative to expression of any one of SEQ ID NOs: 2-7 or SEQ ID NO:1, wherein the polynucleotide does not have the nucleic acid sequence of SEQ ID NO:1; and (b) any one or more of the following features: (i) a 3′ inverted terminal repeat 3′ ITR with a length greater than 135 base pairs (bp) and less than 145 bp; (ii) fewer CpG dinucleotides as compared to a nucleic acid sequence of any one or more of SEQ ID NOs: 9-12 and 35-40; and (iii) fewer restriction enzyme recognition sites as compared to a nucleic acid sequence of any one or more of SEQ ID NOs: 9-12 and 35-40.
Further aspects of the invention provide recombinant expression vectors, recombinant adeno-associated viruses (rAAVs), and compositions related to the inventive polynucleotide expression cassettes.
Another aspect of the invention provides methods of treating a disease or condition mediated by PCC, comprising administering to a subject in need thereof a therapeutic amount of any of the inventive polynucleotide expression cassettes, recombinant expression vectors, rAAVs, or compositions described herein.
Another aspect of the invention provides methods of treating a disease or condition mediated by PCC in a subject in need thereof, comprising administering to a cell of the subject, or a population of cells of the subject, any of the inventive polynucleotide expression cassettes, recombinant expression vectors, rAAVs, or compositions described herein, wherein the polynucleotide expression cassette is inserted into the cell of the subject, or the population of cells of the subject, via genome editing on the cell of the subject, or the population of cells of the subject, using a nuclease selected from the group of zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), the clustered regularly interspaced short palindromic repeats (CRISPR/cas system) and meganuclease re-engineered homing endonucleases on the cell from the subject, or the population of cells of the subject; and administering the cell, or population of cells, to the subject.
Still another aspect of the invention provides a nucleic acid consisting of (a) a nucleotide sequence that is at least 12 but no more than 35 contiguous nucleotides of any one of SEQ ID NO: 2-7; (b) a nucleotide sequence that is at least 90% identical to at least 12 but no more than 35 contiguous nucleotides of any one of SEQ ID NO: 2-7; or (c) a nucleotide sequence that is complementary to (a) or (b).
Another aspect of the invention provides an in vitro method for detecting the expression of synPCCA nucleic acid by cells, the method comprising: (a) contacting a sample comprising nucleic acid from the cells with any of the inventive nucleic acids or collections of nucleic acids described herein, thereby forming a complex; and (b) detecting the complex, wherein detection of the complex is indicative of the expression of synPCCA nucleic acid by the cells.
Polynucleotide expression cassettes have been designed which provide any one or more of a variety of advantages over other recombinant expression vectors comprising a synthetic propionyl-CoA carboxylase subunit a (PCCA) polynucleotide (synPCCA), for example, those described in U.S. patent application Ser. No. 17/620,331, which is incorporated herein by reference in its entirety. For example, the inventive polynucleotide expression cassettes may provide any one or more of reduced immunogenicity, improved packaging, improved stability, and higher titer yield, as compared to other recombinant expression vectors comprising synPCCA, for example, those described in U.S. patent application Ser. No. 17/620,331 (e.g., a nucleic acid sequence of any one or more of SEQ ID NOs: 9-12 and 35-40). For example, in the field of molecular cloning, modifications to expression cassettes often may, disadvantageously, reduce the titer yield. In contrast, the inventive polynucleotide expression cassettes may provide a high titer yield, which is not always achieved with polynucleotide expression cassettes in the field of molecular cloning. The inventive polynucleotide expression cassettes may also provide any one or both of fewer CpG dinucleotides and fewer restriction enzyme recognition sites as compared to other recombinant expression vectors comprising synPCCA, for example, those described in U.S. patent application Ser. No. 17/620,331 (e.g., a nucleic acid sequence of any one or more of SEQ ID NOs: 9-12 and 35-40). Because CpG dinucleotides can potentially stimulate an undesirable immune response in a patient, the inventive polynucleotide expression cassettes may provide reduced immunogenicity as compared to other recombinant expression vectors comprising synPCCA, for example, those described in U.S. patent application Ser. No. 17/620,331 (e.g., a nucleic acid sequence of any one or more of SEQ ID NOs: 9-12 and 35-40).
Accordingly, an aspect of the invention provides a polynucleotide expression cassette comprising: (a) a synPCCA polynucleotide and (b) any one or more of the following features: (i) a 3′ inverted terminal repeat (3′ ITR) with a length greater than 135 base pairs (bp) and less than 145 bp; (ii) fewer CpG dinucleotides as compared to a nucleic acid sequence of any one or more of SEQ ID NOs: 9-12 and 35-40; and (iii) fewer restriction enzyme recognition sites as compared to a nucleic acid sequence of any one or more of SEQ ID NOs: 9-12 and 35-40.
In an aspect of the invention, the 3′ ITR has a length that is greater than 135 bp and less than 145 bp, greater than 136 bp and less than 144 bp, greater than 137 bp and less than 143 bp, or greater than 138 bp and less than 142 bp. In a preferred aspect of the invention, the 3′ ITR has a length of 141 bp.
The 3′ ITR and the 5′ ITR of the polynucleotide expression cassette may be heterologous. In an aspect of the invention, the polynucleotide expression cassette comprises a 5′ inverted terminal repeat (5′ ITR) with a length greater than 125 base pairs (bp) and less than 135 bp. In an aspect of the invention, the 5′ ITR has a length that is greater than 126 bp and less than 134 bp, greater than 127 bp and less than 133 bp, greater than 128 bp and less than 132 bp, or greater than 129 bp and less than 131 bp. In a preferred aspect of the invention, the 5′ ITR has a length of 130 bp.
In an aspect of the invention, the polynucleotide expression cassette has fewer CpG dinucleotides as compared to other recombinant expression vectors comprising synPCCA, for example, a nucleic acid sequence of any one or more of SEQ ID NOs: 9-12 and 35-40. In a CpG dinucleotide, cytidine is joined by a 5′ to 3′ phospho-diester linkage to guanidine as part of a DNA strand. In an aspect of the invention, the polynucleotide expression cassette has fewer CpG dinucleotides near the 3′ ITR, the 5′ ITR, or both the 3′ ITR and the 5′ ITR, as compared to other recombinant expression vectors comprising synPCCA, such as those described in the foregoing paragraph.
For example, the inventive polynucleotide expression cassette may comprise 1% fewer, 2% fewer, 3% fewer, 4% fewer, 5% fewer, 6% fewer, 7% fewer, 8% fewer, 9% fewer, 10% fewer, 11% fewer, 12% fewer, 13% fewer, 14% fewer, 15% fewer, 16% fewer, 17% fewer, 18% fewer, 19% fewer, 20% fewer, 21% fewer, 22% fewer, 23% fewer, 24% fewer, 25% fewer, 26% fewer, 27% fewer, 28% fewer, 29% fewer, 30% fewer, 31% fewer, 32% fewer, 33% fewer, 34% fewer, 35% fewer, 36% fewer, 37% fewer, 38% fewer, 39% fewer, 40% fewer, 41% fewer, 42% fewer, 43% fewer, 44% fewer, 45% fewer, 46% fewer, 47% fewer, 48% fewer, 49% fewer, 50% fewer, 51% fewer, 52% fewer, 53% fewer, 54% fewer, 55% fewer, 56% fewer, 57% fewer, 58% fewer, 59% fewer, 60% fewer, 61% fewer, 62% fewer, 63% fewer, 64% fewer, 65% fewer, 66% fewer, 67% fewer, 68% fewer, 69% fewer, 70% fewer, 71% fewer, 72% fewer, 73% fewer, 74% fewer, 75% fewer, 76% fewer, 77% fewer, 78% fewer, 79% fewer, 80% fewer, 81% fewer, 82% fewer, 83% fewer, 84% fewer, 85% fewer, 86% fewer, 87% fewer, 88% fewer, 89% fewer, 90% fewer, 91% fewer, 92% fewer, 93% fewer, 94% fewer, 95% fewer, 96% fewer, 97% fewer, 98% fewer, or 99% fewer CpG dinucleotides as compared to other recombinant expression vectors comprising synPCCA, for example, a nucleic acid sequence of any one or more of SEQ ID NOs: 9-12 and 35-40In an aspect, the inventive polynucleotide expression cassette may comprise no CpG dinucleotides.
In an aspect of the invention, the polynucleotide expression cassette has fewer restriction enzyme recognition sites as compared to other recombinant expression vectors comprising synPCCA, for example, a nucleic acid sequence of any one or more of SEQ ID NOs: 9-12 and 35-40. Restriction enzyme recognition sites are located on a polynucleotide molecules, e.g., a DNA molecule, and contain specific sequences of nucleotides (e.g., 4 to 8 base pairs in length), which are recognized by restriction enzymes. Restriction enzyme recognition sites are well-known in the art. An example of a restriction enzyme recognition site, the occurrences of which are reduced or eliminated in the inventive polynucleotide expression cassettes, is an attachment L (AttL) site.
For example, the inventive polynucleotide expression cassette may comprise 1% fewer, 2% fewer, 3% fewer, 4% fewer, 5% fewer, 6% fewer, 7% fewer, 8% fewer, 9% fewer, 10% fewer, 11% fewer, 12% fewer, 13% fewer, 14% fewer, 15% fewer, 16% fewer, 17% fewer, 18% fewer, 19% fewer, 20% fewer, 21% fewer, 22% fewer, 23% fewer, 24% fewer, 25% fewer, 26% fewer, 27% fewer, 28% fewer, 29% fewer, 30% fewer, 31% fewer, 32% fewer, 33% fewer, 34% fewer, 35% fewer, 36% fewer, 37% fewer, 38% fewer, 39% fewer, 40% fewer, 41% fewer, 42% fewer, 43% fewer, 44% fewer, 45% fewer, 46% fewer, 47% fewer, 48% fewer, 49% fewer, 50% fewer, 51% fewer, 52% fewer, 53% fewer, 54% fewer, 55% fewer, 56% fewer, 57% fewer, 58% fewer, 59% fewer, 60% fewer, 61% fewer, 62% fewer, 63% fewer, 64% fewer, 65% fewer, 66% fewer, 67% fewer, 68% fewer, 69% fewer, 70% fewer, 71% fewer, 72% fewer, 73% fewer, 74% fewer, 75% fewer, 76% fewer, 77% fewer, 78% fewer, 79% fewer, 80% fewer, 81% fewer, 82% fewer, 83% fewer, 84% fewer, 85% fewer, 86% fewer, 87% fewer, 88% fewer, 89% fewer, 90% fewer, 91% fewer, 92% fewer, 93% fewer, 94% fewer, 95% fewer, 96% fewer, 97% fewer, 98% fewer, or 99% fewer restriction enzyme recognition sites as compared to other recombinant expression vectors comprising synPCCA, for example, a nucleic acid sequence of any one or more of SEQ ID NOs: 9-12 and 35-40.
The synPCCA polynucleotide may be as described, for example, in U.S. patent application Ser. No. 17/620,331. In the context of synPCCA, the terms “gene” and “transgene” are used interchangeably. A “transgene” is a gene that has been transferred from one organism to another. The polynucleotide sequences encoding the alpha subunit of PCC, synPCCA, allow for increased expression of the synPCCA gene relative to naturally occurring human PCCA sequences. These polynucleotide sequences are designed to not alter the naturally occurring human PCC alpha subunit amino acid sequence. They are also engineered or optimized to have increased transcriptional, translational, and protein refolding efficacy. This engineering is accomplished by using human codon biases, evaluating GC, CpG, and negative GpC content, optimizing the interaction between the codon and anti-codon, and eliminating cryptic splicing sites and RNA instability motifs. The synPCCA polynucleotides may also facilitate detection using nucleic acid-based assays.
As used herein, “PCCA” refers to the alpha subunit of human propionyl-CoA carboxylase, and “Pcca” refers to the alpha subunit of mouse propionyl-CoA carboxylase. PCC catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA which is a metabolic precursor to succinyl-CoA, a component of the citric acid cycle or tricarboxylic acid cycle (TCA). The genes encoding the alpha and beta subunits of naturally occurring human propionyl-CoA carboxylase gene are referred to as PCCA or PCCB, respectively. The synthetic polynucleotide encoding the alpha subunit of PCC is referred to as synPCCA.
Naturally occurring human propionyl-CoA carboxylase is referred to as PCC, while synthetic PCC is designated as synPCC, even though the two are identical at the amino acid level.
“Codon optimization” refers to the process of altering a naturally occurring polynucleotide sequence to enhance expression in the target organism, e.g., humans. In the subject application, the human PCCA gene has been altered to replace codons that occur less frequently in human genes with those that occur more frequently and/or with codons that are frequently found in highly expressed human genes, see
Codon optimization was employed to create six highly active and synthetic PCCA alleles designated PCCA1-6. This method involves determining the relative frequency of a codon in the protein-encoding genes in the human genome. For example, isoleucine can be encoded by AUU, AUC, or AUA, but in the human genome, AUC (47%), AUU (36%), and AUA (17%) are variably used to encode isoleucine in proteins. Therefore, in the proper sequence context, AUA would be changed to AUC to allow this codon to be more efficiently translated in human cells.
Thus, the polynucleotide expression cassette comprises synthetic polynucleotides encoding PCCA selected from the group consisting of SEQ ID NOs: 2-7 and a polynucleotide sequence having at least 80% identity thereto. For those polynucleotides having at least 80% identity to SEQ ID NOs: 2-7, in additional aspects, they have at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NOs: 2-7.
In one aspect, the subject synthetic polynucleotide encodes a polypeptide with 100% identity to the naturally occurring human PCC protein.
In another aspect, SEQ ID NOs:2-7 encode a PCC alpha subunit that has 100% identity with the naturally occurring human PCC alpha subunit protein, or that has at least 90% amino acid identity to the naturally occurring human PCC alpha subunit protein. In a preferred aspect, the polynucleotide encodes a PCC alpha subunit protein that has at least 95% amino acid identity to naturally occurring human PCC alpha subunit protein.
In one aspect, a polypeptide encoded by the polynucleotide expression cassette retains at least 90% of the naturally occurring human PCC protein function, i.e., the capacity to catalyze the carboxylation of propionyl-CoA to D-methylmalonyl-CoA. In another aspect, the encoded PCC protein retains at least 95% of the naturally occurring human PCC protein function. This protein function can be measured, for example, via the efficacy to rescue a neonatal lethal phenotype in Pcca knock-out mice (
In some aspects, the synPCCA polynucleotide exhibits improved expression relative to the expression of naturally occurring human propionyl-CoA carboxylase alpha polynucleotide sequence. The improved expression is due to the polynucleotide comprising codons that have been optimized relative to the naturally occurring human propionyl-CoA carboxylase alpha polynucleotide sequence. In one aspect, the synthetic polynucleotide has at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80% of less commonly used codons replaced with more commonly used codons. In additional aspects, the polynucleotide has at least 85%, 90%, or 95% replacement of less commonly used codons with more commonly used codons, and demonstrate equivalent or enhanced expression of PCCA as compared to SEQ ID NO:1.
In some aspects, the synPCCA polynucleotide preferably encodes a polypeptide that retains at least 80% of the enhanced PCC expression (as demonstrated by expression of the polynucleotide of SEQ ID NO:1 in an appropriate host.) In additional aspects, the polypeptide retains at least 85%, 90%, or 95% or 100% of the enhanced expression observed with the polynucleotides of SEQ ID NOs: 2-7.
In designing the synPCCA, the following considerations were balanced. For example, fewer changes to the nucleotide sequence of SEQ ID NO:1 may decrease the potential of altering the secondary structure of the sequence, which can have a significant impact on gene expression. The introduction of undesirable restriction sites is also reduced, which may facilitate the subcloning of PCCA into the plasmid expression vector. However, a greater number of changes to the nucleotide sequence of SEQ ID NO:1 may allow for more convenient identification of the translated and expressed message, e.g. mRNA, in vivo. Additionally, a greater number of changes to the nucleotide sequence of SEQ ID NO:1 may increase the likelihood of greater expression. These considerations were balanced when arriving at SEQ ID NOs: 2-7. The polynucleotide sequences encoding synPCCA may allow for increased expression of the synPCCA gene relative to naturally occurring human PCCA sequences. They are also engineered to have increased transcriptional, translational, and protein refolding efficacy. This engineering is accomplished by using human codon biases, evaluating GC, CpG, and negative GpC content, optimizing the interaction between the codon and anti-codon, and eliminating cryptic splicing sites and RNA instability motifs. The synPCCA polynucleotides may facilitate detection using nucleic acid-based assays.
PCCA has a total of 728 amino acids and synPCCA contains 728 codons corresponding to said amino acids. In SEQ ID NOs: 2-7, codons were changed from that of the natural human PCCA. However, despite changes from SEQ ID NO:1, SEQ ID NOs: 2-7 encode the amino acid sequence SEQ ID NO:8 of PCCA. Codons for SEQ ID NOs: 2-7 are changed, in accordance with the equivalent amino acid positions of SEQ ID NO:8, as seen in Table 2. In this aspect, the amino acid sequence for natural human PCCA has been retained.
It can be appreciated that partial reversion of the designed synPCCA to codons that are found in PCCA can be expected to result in nucleic acid sequences that, when incorporated into appropriate vectors, can also exhibit the desirable properties of SEQ ID NOs: 2-7. For example, such partial reversion or hybrid variants can have PCCA expression from a vector inserted into an appropriate host that is equivalent to that of SEQ ID NOs: 2-7. For example, aspects of the invention include nucleic acids in which at least 1 altered codon, at least 2 altered codons, at least 3 altered codons, at least 4 altered codons, at least 5 altered codons, at least 6 altered codons, at least 7 altered codons, at least 8 altered codons, at least 9 altered codons, at least 10 altered codons, at least 11 altered codons, at least 12 altered codons, at least 13 altered codons, at least 14 altered codons, at least 15 altered codons, at least 16 altered codons, at least 17 altered codons, at least 18 altered codons, at least 20 altered codons, at least 25 altered codons, at least 30 altered codons, at least 35 altered codons, at least 40 altered codons, at least 50 altered codons, at least 55 altered codons, at least 60 altered codons, at least 65 altered codons, at least 70 altered codons, at least 75 altered codons, at least 80 altered codons, at least 85 altered codons, at least 90 altered codons, at least 95 altered codons, at least 100 altered codons, at least 110 altered codons, at least 120 altered codons, at least 130 altered codons, at least 130 altered codons, at least 140 altered codons, at least 150 altered codons, at least 160 altered codons, at least 170 altered codons, at least 180 altered codons, at least 190 altered codons, at least 200 altered codons, at least 220 altered codons, at least 240 altered codons, at least 260 altered codons, at least 280 altered codons, at least 300 altered codons, at least 320 altered codons, at least 340 altered codons, at least 360 altered codons, at least 380 altered codons, at least 400 altered codons, at least 420 altered codons, at least 440 altered codons, at least 460 altered codons, or at least 480 altered codons in SEQ ID NOs: 2-7 are reverted to native codons according to SEQ ID NO:1, and having expression equivalent to that of SEQ ID NO:1. Alternately, at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the altered codons in SEQ ID NOs:2-7 are reverted to the native sequence according to SEQ ID NO:1, and having expression that is equivalent to that of SEQ ID NOs: 2-7.
In some aspects, the polynucleotide expression cassettes do not comprise a polynucleotide that shares 100% identity with SEQ ID NO:1. In other words, in some aspects, polynucleotides having 100% identity with SEQ ID NO:1 are excluded from the aspects of the present invention.
The synthetic polynucleotide can be composed of DNA and/or RNA or a modified nucleic acid, such as a peptide nucleic acid, and could be conjugated for improved biological properties.
In one aspect, the polynucleotide expression cassette comprises a synPCCA polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleic acid sequence of any one of SEQ ID NOs:2-7; (b) a polynucleotide having the nucleic acid sequence of any one of SEQ ID NOs:2-7; (c) a polynucleotide having a nucleic acid sequence with at least 80% identity to the nucleic acid sequence of any one of SEQ ID NOs:2-7; (d) a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO:8 or an amino acid sequence substantially identical to the amino acid sequence of SEQ ID NO:8, wherein the polynucleotide does not have the nucleic acid sequence of SEQ ID NO:1; and (e) a polynucleotide encoding an active fragment of the PCC protein, wherein the polynucleotide in its entirety does not share 100% identity with a portion of the nucleic acid sequence of SEQ ID NO:1.
The phrase “substantially identical”, as used herein, refers to an amino acid sequence exhibiting high identity with a reference amino acid sequence (for example, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 98%, or at least 99%) and retaining the biological activity of interest (the enzyme activity).
In one aspect, the synPCCA polynucleotide is selected from the group consisting of: a polynucleotide comprising the nucleic acid sequence of any one of SEQ ID NOs: 2-7; a polynucleotide comprising a nucleic acid sequence with at least 80% identity to the nucleic acid sequence of any one of SEQ ID NOs: 2-7 which encodes the polypeptide of SEQ ID NO:8 and has equivalent or greater expression in a host relative to expression of any one of SEQ ID NOs: 2-7 or SEQ ID NO:1, wherein the polynucleotide does not have the nucleic acid sequence of SEQ ID NO:1. In one aspect, the synthetic polynucleotide has at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, or 99% identity to the nucleic acid sequence of any one of SEQ ID NOs:2-7. Another example of a synthetic polynucleotide comprises the nucleotide sequence of SEQ ID NO: 43 (truncated PCCA) or a nucleotide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, or 99% identity to the nucleic acid sequence of SEQ ID NO 43.
The fragment may include only amino acid residues encoded by synPCCA, which represents the active, processed form of PCC alpha. By active can be meant, for example, the enzyme's ability to catalyze the carboxylation of propionyl CoA to D-methylmalonyl CoA. The activity can be assayed using methods and assays well-known in the art (as described in the context of protein function, below).
The synPCCA polynucleotide encodes a polypeptide having the amino acid sequence of SEQ ID NO:8 or an amino acid sequence with at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO:8.
The synPCCA polynucleotide may exhibit augmented expression relative to the expression of naturally occurring human propionyl-CoA carboxylase alpha polynucleotide sequence (SEQ ID NO:1) in a subject. The synPCCA polynucleotide with augmented expression may comprise a nucleic acid sequence comprising codons that have been optimized relative to the naturally occurring human propionyl-CoA carboxylase alpha polynucleotide sequence (SEQ ID NO:1). The synPCCA polynucleotide may have at least 80% of less commonly used codons replaced with more commonly used codons.
The synPCCA polynucleotide may have a nucleic acid sequence with at least 85% identity to the nucleic acid sequence of any one of SEQ ID NOs: 2-7. In other aspects, the synPCCA polynucleotide has a nucleic acid sequence with at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 98%, at least 99%, or 100% identity to the nucleic acid sequence of any one of SEQ ID NOs: 2-7.
The synPCCA polynucleotide may be a DNA sequence. The synPCCA polynucleotide may be a RNA sequence or peptide modified nucleic acid sequence. The synPCCA polynucleotide may encode an active PCC alpha fragment.
In another aspect, the invention is directed to a recombinant expression vector comprising the herein-described polynucleotide expression cassette. In another aspect of a vector according to the invention, the synPCCA polynucleotide is operably linked to an expression control sequence. In still another aspect, the synPCCA polynucleotide is codon-optimized.
In one aspect, the recombinant expression vector comprising the polynucleotide expression cassette is an AAV vector containing the chicken-beta actin promoter (SEQ ID NO:9), the EF1AL promoter (SEQ ID NO:10), the elongation factor 1 alpha short promoter with a 3′ HPRE (SEQ ID NO: 11), or the short elongation factor 1 alpha promoter with a mutant 3′ HPRE (SEQ ID NO:12).
In another aspect, the recombinant expression vector comprising the polynucleotide expression cassette is an AAV vector containing a liver specific enhancer and promoter, such as the long (SEQ ID NO:14) or short variants (SEQ ID NO:13) of the apolipoprotein E enhancer, operably linked to the long (SEQ ID NO:16) or short variants of the human alpha 1 antitrypsin promoter (SEQ ID NO:15) and followed by either a chimeric intron (SEQ ID NO: 17), modified beta (β)-globin intron (SEQ ID NO: 18), or a synthetic intron (SEQ ID NO:19).
In one aspect, the apolipoprotein E enhancer, and human alpha 1 antitrypsin promoter are operably linked to form a short (SEQ ID NO: 20) or long liver specific enhancer-promoter unit (SEQ ID NO: 21) and placed 5′ to an intron selected from SEQ ID NO: 17-19. In one aspect, the intron is the modified β-globin intron (SEQ ID NO: 18).
In a further aspect, the enhanced human alpha 1 antitrypsin enhancer, promoter, and intron comprises SEQ ID:22.
In another aspect, the liver specific enhancer is derived from sequences upstream of the alpha-1-microglobulin/bikunin precursor (SEQ ID:23 and SEQ ID:24), operably linked to the human thyroxine-binding globulin promoter (TBG) (SEQ ID:25).
In one aspect, the liver specific enhancer and human thyroxine-binding globulin promoter is SEQ ID:26.
The polynucleotide expression cassette of the disclosure can include additional features. For example, the synPCCA polynucleotide can be flanked by a 5′ untranslated region (5′UTR) that includes a strong Kozak translational initiation signal. A 5′UTR can comprise a heterologous polynucleotide fragment and a then a second, third or fourth polynucleotide fragment from the same and/or different UTRs.
In some aspects, the polynucleotide expression cassette of the disclosure comprises an internal ribosome entry site (RES) (SEQ ID: 27) instead of, or in addition to, a UTR.
In one aspect, the UTR can also include at least one translation enhancer element (TEE). A TEE comprises nucleic acid sequences that increase the amount of polypeptide or protein produced from a polynucleotide. As a non-limiting example, the TEE can be located between the promoter and the start codon. In some aspects, the 5′UTR comprises a TEE.
In one aspect, the 5′UTR sequence(s) are derived from genes well known to be highly expressed in the liver. Non-limiting examples include polynucleotides derived from human albumin (SEQ ID: 28), SERPINA 1 (SEQ ID: 29), or SERPINA 3 (SEQ ID: 30).
In one aspect, the polynucleotide expression cassettes of the disclosure include additional features, including the incorporation of sequences designed to stabilize the synthetic PCCA mRNA. In one example, the polynucleotide expression cassette comprises the wood chuck post-translational response element (SEQ ID: 31) In another non-limiting example, the polynucleotide expression cassette comprises the hepatitis post-translational response element (SEQ ID:32).
In one aspect, the polynucleotide expression cassette contains a synPCCA polynucleotide including a polyadenylation signal, such as that derived from the rabbit beta globin gene or the bovine growth hormone gene. Such sequences are well known to practitioners of the art.
In one aspect, terminal repeat sequences (SEQ ID:33-34) from the piggyBac transposon, which is originally isolated from the cabbage looper (Trichoplusia ni; a moth species), are inserted immediately after the 5′AAV ITR and before the 3′ AAV ITR. piggyBac is a class II transposon, moving in a cut-and-paste manner. An AAV vector that contains piggyBac terminal repeat sequences can serve as a substrate for piggyBac transposase, which, when introduced by a viral or non-viral vector, can mediate the permanent integration of the AAV polynucleotide expression cassette containing the synPCCA polynucleotide into the transduced cell. Hybrid AAV-piggyBac transposon vectors are well understood by practitioners of the art, and can be used to deliver the synPCCA polynucleotide to a target cell in vitro and in vivo.
One aspect of a AAV recombinant expression vector comprising a polynucleotide expression cassette designed to express synPCCA1 incorporates the enhanced TBG promoter of SEQ ID:35.
In one aspect, a AAV recombinant expression vector comprising a polynucleotide expression cassette designed to express synPCCA1 incorporates the enhanced human alpha 1 antitrypsin promoter of SEQ ID:36.
In one aspect, the polynucleotide expression cassettes are configured to integrate into the human albumin locus. A donor cassette is constructed that targets the stop codon of human albumin, which yields, after homologous recombination, synPCCA1 that is fused via a P2 peptide to the carboxy terminus of albumin.
In one aspect, the vector that is an integrating AAV vector, from 5′ITR to 3′ITR, that uses homologous recombination to insert the polynucleotide expression cassette into the end of Albumin, which is a safe harbor for gene editing, is SEQ ID:37.
In one aspect, the integrating AAV vector, from 5 ITR to 3′ITR, that uses homologous recombination to insert the polynucleotide expression cassette into 5′ end of Albumin is SEQ ID:38.
In one aspect, the polynucleotide expression cassettes of this application are configured to integrate into the genome after delivery using a lentiviral vector.
In one aspect, a lentiviral vector is designed to express the polynucleotide expression cassette using an enhanced human alpha 1 antitrypsin enhancer and promoter of SEQ ID:39.
In yet another aspect, a lentiviral vector designed to express the polynucleotide expression cassette using the elongation factor 1 long promoter is SEQ ID:40.
In an aspect of the invention, the polynucleotide expression cassette further comprises any one or more of the following features: (i) a 5′ ITR nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to nucleotides 1 to 130 of SEQ ID NO: 41; (ii) a core elongation factor 1 alpha (EF1S) promoter nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to nucleotides 131 to 361 of SEQ ID NO: 41; (iii) an intron nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to nucleotides 362 to 526 of SEQ ID NO: 41; (iv) a HPRE nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to nucleotides 2714 to 3439 of SEQ ID NO: 41; (v) a polyA nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to nucleotides 3440 to 3664 of SEQ ID NO: 41; and (vi) a 3′ ITR nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to nucleotides 3665 to 3805 of SEQ ID NO: 41.
In an aspect of the invention, the polynucleotide expression cassette further comprises all of the following features: (i) a 5′ ITR nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to nucleotides 1 to 130 of SEQ ID NO: 41; (ii) a EF1S promoter nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to nucleotides 131 to 361 of SEQ ID NO: 41; (iii) an intron nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to nucleotides 362 to 526 of SEQ ID NO: 41; (iv) a HPRE nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to nucleotides 2714 to 3439 of SEQ ID NO: 41; (v) a polyA nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to nucleotides 3440 to 3664 of SEQ ID NO: 41; and (vi) a 3′ ITR nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to nucleotides 3665 to 3805 of SEQ ID NO: 41.
In an aspect of the invention, the synPCCA polynucleotide comprises a synPCCA1 nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to SEQ ID NO: 2.
In an aspect of the invention, the polynucleotide expression cassette comprises any one or more of the following features: (i) a 5′ ITR nucleotide sequence consisting of a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to nucleotides 1 to 130 of SEQ ID NO: 41; (ii) a EF1S promoter nucleotide sequence consisting of a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to nucleotides 131 to 361 of SEQ ID NO: 41; (iii) a intron nucleotide sequence consisting of a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to nucleotides 362 to 526 of SEQ ID NO: 41; (iv) a HPRE nucleotide sequence consisting of a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to nucleotides 2714 to 3439 of SEQ ID NO: 41; (v) a polyA nucleotide sequence consisting of a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to nucleotides 3440 to 3664 of SEQ ID NO: 41; and (vi) a 3′ ITR nucleotide sequence consisting of a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to nucleotides 3665 to 3805 of SEQ ID NO: 41.
In an aspect of the invention, the polynucleotide expression cassette comprises all of the following features: (i) a 5′ ITR nucleotide sequence consisting of a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to nucleotides 1 to 130 of SEQ ID NO: 41; (ii) a EF1S promoter nucleotide sequence consisting of a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to nucleotides 131 to 361 of SEQ ID NO: 41; (iii) a intron nucleotide sequence consisting of a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to nucleotides 362 to 526 of SEQ ID NO: 41; (iv) a HPRE nucleotide sequence consisting of a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to nucleotides 2714 to 3439 of SEQ ID NO: 41; (v) a polyA nucleotide sequence consisting of a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to nucleotides 3440 to 3664 of SEQ ID NO: 41; and (vi) a 3′ ITR nucleotide sequence consisting of a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to nucleotides 3665 to 3805 of SEQ ID NO: 41.
In an aspect of the invention, the synPCCA polynucleotide consists of a synPCCA1 nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to SEQ ID NO: 2.
In an aspect of the invention, the polynucleotide expression cassette comprises a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% identical to SEQ ID NO: 41 or SEQ ID NO: 42.
In an aspect of the invention, the polynucleotide expression cassette consists of a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%. 98%, 99%, or 100% identical to the nucleotide sequence of SEQ ID NO: 41 or SEQ ID NO: 42. Another example of a recombinant expression vector is the nucleotide sequence of SEQ ID NO: 44.
Aspects of the invention may provide recombinant expression vectors comprising any of the inventive polynucleotide expression cassettes described herein. The vector may be a recombinant adeno-associated virus (rAAV). The rAAV may comprise an AAV capsid and a vector genome packaged therein. The vector genome may comprise: a 5′-inverted terminal repeat sequence (5′-ITR) sequence; a promoter sequence; a 5′ untranslated region; a Kozak sequence; a partial fragment or complete coding sequence for PCCA; an mRNA stability sequence; a polyadenylation signal; and a 3′-inverted terminal repeat sequence (3′-ITR) sequence. In one aspect, the rAAV is comprised of the structure in
Any of the inventive polynucleotide expression cassettes, recombinant expression vectors, rAAVs, or compositions described herein can be used as a drug, via viral- or non-viral mediated gene delivery, to restore PCC function in PA patients, prevent metabolic instability, and ameliorate disease progression. Because this enzyme is involved in other human disorders of branched chain amino acid oxidation, gene delivery of a synthetic PCCA gene might used to treat conditions other than PA.
In another aspect, the invention comprises a method of treating a disease or condition mediated by PCC, comprising administering to a subject in need thereof a therapeutic amount of any of the inventive polynucleotide expression cassettes, recombinant expression vectors, rAAVs, or compositions described herein. The disease or condition can, in one aspect, be PA. The PCC enzyme is processed after transcription, translation, and translocation into the mitochondrial inner space.
Enzyme replacement therapy includes administration of the functional enzyme (PCC) to a subject in a manner so that the enzyme administered will catalyze the reactions in the body that the subject's own defective or deleted enzyme cannot. In enzyme therapy, the defective enzyme can be replaced in vivo or repaired in vitro using the polynucleotide expression cassette according to the invention. The functional enzyme molecule can be isolated or produced in vitro, for example. Methods for producing recombinant enzymes in vitro are known in the art. In vitro enzyme expression systems include, without limitation, cell-based systems (bacterial (for example, Escherichia coli, Corynebacterium, Pseudomonas fluorescens), yeast (for example, Saccharomyces cerevisiae, Pichia Pastoris), insect cell (for example, Baculovirus-infected insect cells, non-lytic insect cell expression), and eukaryotic systems (for example, Leishmania)) and cell-free systems (using purified RNA polymerase, ribosomes, tRNA, ribonucleotides). Viral in vitro expression systems are likewise known in the art. The enzyme isolated or produced according to the above-iterated methods exhibits, in specific aspects, 80%, 85%, 90%, 95%, 98%, 99%, or 100% homology to the naturally occurring (for example, human) PCC.
Gene therapy can involve in vivo gene therapy (direct introduction of the genetic material into the cell or body) or ex vivo gene transfer, which usually involves genetically altering cells prior to administration. In one aspect, genome editing, or genome editing with engineered nucleases (GEEN) may be performed with the polynucleotide expression cassettes of the present invention allowing synPCCA DNA to be inserted, replaced, or removed from a genome using artificially engineered nucleases. Any known engineered nuclease may be used such as ZFNs, TALENs, the CRISPR/Cas system, and engineered meganuclease re-engineered homing endonucleases. Alternately, the nucleotides of the present invention including synPCCA, in combination with a CASP/CRISPR, ZFN, or TALEN can be used to engineer correction at the locus in a patient's cell either in vivo or ex vivo, then, in one aspect, use that corrected cell, such as a fibroblast or lymphoblast, to create an iPS or other stem cell for use in cellular therapy.
In one aspect, the method of treating a disease or condition mediated by PCC in a subject in need thereof, comprising administering to a cell of the subject, or a population of cells of the subject, any of the inventive polynucleotide expression cassettes, recombinant expression vectors, rAAVs, or compositions described herein, wherein the polynucleotide expression cassette is inserted into the cell of the subject, or the population of cells of the subject, via genome editing on the cell of the subject, or the population of cells of the subject, using a nuclease selected from the group of ZFNs, TALENs, the CRISPR/cas system and meganuclease re-engineered homing endonucleases on the cell from the subject, or the population of cells of the subject; and administering the cell, or population of cells, to the subject.
In another aspect, the polynucleotide expression cassettes of the present invention can be used in combination with a non-integrating vector or as naked DNA, and configured to contain terminal repeat sequences for a transposon recognition by a transposase such as piggyBac. The use of hybrid AAV and adenoviral vectors that combine the transient or regulated expression of a transposase like piggyBac may be performed to enable permanent correction by cut and paste transposition. Alternatively, the transposase mRNA, encapsulated as lipid-nanoparticle, might be used to deliver piggBac transposase.
In one aspect, the invention is directed to a method of treating a disease or condition mediated by PCC or low levels of PCC activity, the method comprising administering to a subject any of the inventive polynucleotide expression cassettes, recombinant expression vectors, rAAVs, or compositions described herein.
In one aspect, the invention is directed to a method of treating a disease or condition mediated by PCC, the method comprising administering to a subject a PCC produced using any of the inventive polynucleotide expression cassettes, recombinant expression vectors, rAAVs, or compositions described herein. In another aspect of a method of treatment according to the invention, the disease or condition is PA.
In one aspect, the invention is directed to the preclinical amelioration or rescue from the disease state, for example, propionic acidemia, that the afflicted subject exhibits. This may include symptoms, such as lethargy, lethality, metabolic acidosis, and biochemical perturbations, such as increased levels of methylcitrate in blood, urine, and body fluids.
Additionally, any of the inventive polynucleotide expression cassettes, recombinant expression vectors, rAAVs, or compositions described herein can be used for the in vitro production of PA for use in enzyme replacement therapy for PA. Enzyme replacement therapy may be accomplished by administration of the synthetic PCC protein, sub-cutaneously, intra-muscularly, intravenously, or by other therapeutic delivery routes.
The term “subject”, as used herein, refers to a domesticated animal, a farm animal, a primate, a mammal, for example, a human.
Routes of delivery of a synPCCA polynucleotide expression cassette according to the invention may include, without limitation, injection (systemic or at target site), for example, intradermal, subcutaneous, intravenous, intraperitoneal, intraocular, subretinal, renal artery, hepatic vein, intramuscular injection; physical, including ultrasound (-mediated transfection), electric field-induced molecular vibration, electroporation, transfection using laser irradiation, photochemical transfection, gene gun (particle bombardment); parenteral and oral (including inhalation aerosols and the like). Related methods include using genetically modified cells.
In one aspect, the polynucleotide expression cassette, recombinant expression vector, rAAV, or composition is administered subcutaneously, intramuscularly, intradermally, intraperitoneally, or intravenously.
In one aspect, the rAAV is administered at a dose of 1×1011 to 1×1014 genome copies (GC)/kg.
In one aspect, the administering the rAAV comprises administration of a single dose of rAAV; in one aspect, administering the rAAV comprises administration of multiple doses of rAAV.
Vehicles for delivery of a synthetic propionyl-CoA carboxylase (synPCCA) polynucleotide expression cassette according to the invention may include, without limitation, viral vectors (for example, AAV, integrating AAV vectors, adenovirus, baculovirus, retrovirus, lentivirus, foamy virus, herpes virus, Moloney murine leukemia virus, Vaccinia virus, and hepatitis virus) and non-viral vectors (for example, naked DNA, mini-circles, liposomes, ligand-polylysine-DNA complexes, nanoparticles, including mRNA containing lipid nanoparticles, cationic polymers, including polycationic polymers such as dendrimers, synthetic peptide complexes, artificial chromosomes, and polydispersed polymers). Thus, dosage forms contemplated include injectables, aerosolized particles, capsules, and other oral dosage forms.
In one specific aspect, synPCCA could be placed under the transcriptional control of a ubiquitous or tissue-specific promoter, with a 5′ intron, 5′ intron translational enhancer element, and flanked by an mRNA stability element, such as the woodchuck or hepatitis post-transcriptional regulatory element, and polyadenylation signal. The use of a tissue-specific promoter can restrict unwanted transgene expression, as well as facilitate persistent transgene expression. The therapeutic transgene could then be delivered as coated or naked DNA into the systemic circulation, portal vein, or directly injected into a tissue or organ, such as the liver or kidney. In addition to the liver or kidney, the brain, pancreas, eye, heart, lungs, bone marrow, and muscle may constitute targets for therapy. Other tissues or organs may be additionally contemplated as targets for therapy.
In another aspect, the same polynucleotide expression cassette could be packaged into a viral vector, such as an adenoviral vector, retroviral vector, lentiviral vector, or adeno-associated viral vector, and delivered by various means into the systemic circulation, portal vein, or directly injected into a tissue or organ, such as the liver or kidney. In addition to the liver or kidney, the brain, pancreas, eye, heart, lungs, bone marrow, and muscle may constitute targets for therapy. Other tissues or organs may be additionally contemplated as targets for therapy.
Tissue-specific promoters include, without limitation, Apo A-I, ApoE, hAAT, transthyretin, liver-enriched activator, albumin, TBG, PEPCK, and RNAPII promoters (liver), PAI-1, ICAM-2 (endothelium), MCK, SMC α-actin, myosin heavy-chain, and myosin light-chain promoters (muscle), cytokeratin 18, CFTR (epithelium), GFAP, NSE, Synapsin I, Preproenkephalin, dβH, prolactin, CaMK2, and myelin basic protein promoters (neuronal), and ankyrin, α-spectrin, globin, HLA-DRα, CD4, glucose 6-phosphatase, and dectin-2 promoters (erythroid).
Regulatable promoters (for example, ligand-inducible or stimulus-inducible promoters) and optogenetic promoters are also contemplated for expression constructs according to aspects of the invention.
In yet another aspect, the polynucleotide expression cassette could be used in ex vivo applications via packaging into a retro- or lentiviral vector to create an integrating vector that could be used to permanently correct any cell type from a patient with PCC deficiency. The synPCCA-transduced and corrected cells could then be used as a cellular therapy. Examples might include CD34+ stem cells, primary hepatocytes, or fibroblasts derived from patients with PCC deficiency. Fibroblasts could be reprogrammed to other cell types using iPS methods well known to practitioners of the art. In yet another aspect, the polynucleotide expression cassette could be recombined using genomic engineering techniques that are well known to practitioners of the art, such as ZFNs and TALENS, into the PCCA locus, a genomic safe harbor site, such as AAVS1, or into another advantageous location, such as into rDNA, the albumin locus, GAPDH, or a suitable expressed pseudogene. In yet another aspect, synPCCA could be delivered using a hybrid AAV-piggyBac transposon system as is well known to practitioners of the art (see PMID: 31099022), and references therein: Siew et al., Hepatology, 70(6): 2047-2061 (2019).
Aspects of the invention may further provide compositions comprising (a) any of the inventive polynucleotide expression cassettes, recombinant expression vectors, or rAAVs described herein, and (b) a pharmaceutically acceptable carrier. In one aspect, the composition further comprises a hybrid AAV-piggyBac transposon system.
A composition (pharmaceutical composition) for treating an individual by gene therapy may comprise a therapeutically effective amount of a vector comprising the synPCCA transgenes or a viral particle produced by or obtained from same. The pharmaceutical composition may be for human or animal usage. Typically, a physician will determine the actual dosage which will be most suitable for an individual subject, and it will vary with the age, weight, and response of the particular individual.
The composition may, in specific aspects, comprise a pharmaceutically acceptable carrier, diluent, excipient, or adjuvant. Such materials should be non-toxic and should not interfere with the efficacy of the transgene. Pharmaceutically acceptable excipients include, but are not limited to, liquids such as water, saline, glycerol, sugars and ethanol. Pharmaceutically acceptable salts can also be included therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles. A thorough discussion of pharmaceutically acceptable excipients is available in Remington: The Science and Practice of Pharmacy, 22nd Ed., Pharmaceutical Press (2012). The choice of pharmaceutical carrier, excipient, or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as, or in addition to, the carrier, excipient, or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilizing agent(s), and other carrier agents that may aid or increase the viral entry into the target site (such as for example a lipid delivery system). For oral administration, excipients such as starch or lactose may be used. Flavoring or coloring agents may be included, as well. For parenteral administration, a sterile aqueous solution may be used, optionally containing other substances, such as salts or monosaccharides to make the solution isotonic with blood.
As used herein, a “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. Examples of pharmaceutically acceptable carriers include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. In certain aspects, it may be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition.
A composition according to the invention may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, modulators, or drugs (e.g., antibiotics).
The composition may be in a variety of forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories. Additional dosage forms contemplated include: in the form of a suppository or pessary; in the form of a lotion, solution, cream, ointment or dusting powder; by use of a skin patch; in capsules or ovules; in the form of elixirs, solutions, or suspensions; in the form of tablets or lozenges.
A “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result. A therapeutically effective amount of a vector comprising the polynucleotide expression cassette of the invention may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the vector to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the vector are outweighed by the therapeutically beneficial effects. A “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.
Dosage regimens may be adjusted to provide the optimum desired response (e.g., a therapeutic or prophylactic response). For example, a single bolus may be administered, several divided doses may be administered over time, or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of the polynucleotide expression cassette or a fragment thereof according to the invention calculated to produce the desired therapeutic effect in association with a pharmaceutical carrier.
Nucleic acids consisting of portions of the synPCCA polynucleotides (and nucleic acids comprising nucleotide sequences complementary thereto) may facilitate detection using nucleic acid-based assays. Accordingly, nucleic acids consisting of portions of the synPCCA polynucleotides (and nucleic acids comprising nucleotide sequences complementary thereto) described herein may provide forward primers, reverse primers, and probes which may, advantageously, specifically hybridize with nucleic acid from cells for detection of the expression of synPCCA nucleic acid by the cells. In some aspects, these synPCCA nucleic acids specifically hybridize with nucleic acid from cells. The synPCCA nucleic acids of the invention may provide many advantages. These advantages may include, for example, the rapid, sensitive, and specific detection of the expression of synPCCA nucleic acid by cells.
An aspect of the invention provides a synPCCA nucleic acid consisting of (a) a nucleotide sequence that is at least 12 but no more than 35 contiguous nucleotides of any one of SEQ ID NO: 2-7; (b) a nucleotide sequence that is at least 90% identical to at least 12 but no more than 35 contiguous nucleotides of any one of SEQ ID NO: 2-7; or (c) a nucleotide sequence that is complementary to (a) or (b).
In an aspect of the invention, the synPCCA nucleic acid consists of:
In an aspect of the invention, the synPCCA nucleic acid (e.g., probe) further comprises a detectable label. The label may be any label suitable for detecting hybridization, e.g., a complex, of the synPCCA nucleic acid (e.g., probe) with nucleic acid from cells of a subject. Exemplary detectable labels may include any one or more of radioactive labels, non-radioactive labels, fluorescent labels, and chemiluminescent labels.
Another aspect of the invention provides a collection of synPCCA nucleic acids comprising two or more of any of the synPCCA nucleic acids described herein. In an aspect of the invention, the collection may comprise or further comprise a nucleotide sequence complementary to any of the synPCCA nucleic acids described herein. The collection may comprise any suitable number of inventive synPCCA nucleic acids. For example, the collection may comprise from about 2 to about 75 or more synPCCA nucleic acids, from about 10 or less to about 70 or more synPCCA nucleic acids, from about 20 or less to about 60 or more synPCCA nucleic acids, or from about 30 or less to about 50 or more synPCCA nucleic acids. In this regard, the collection may comprise 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more, 19 or more, 20 or more, 21 or more, 22 or more, 23 or more, 24 or more, 25 or more, 26 or more, 27 or more, 28 or more, 29 or more, 30 or more, 31 or more, 32 or more, 33 or more, 34 or more, 35 or more, 36 or more, 37 or more, 38 or more, 39 or more, 40 or more, 41 or more, 42 or more, 43 or more, 44 or more, 45 or more, 46 or more, 47 or more, 48 or more, 49 or more, 50 or more, 51 or more, 52 or more, 53 or more, 54 or more, 55 or more, 56 or more, 57 or more, 58 or more, 59 or more, 60 or more, 61 or more, 62 or more, 63 or more, 64 or more, 65 or more, 66 or more, 67 or more, 68 or more, 69 or more, 70 or more, 71 or more, 72 or more, 73 or more, or 74 or more synPCCA nucleic acids. Although the two or more synPCCA nucleic acids of the collection may be identical to one another, in a preferred aspect, the two or more synPCCA nucleic acids are different from each other.
In an aspect of the invention, the collection of synPCCA nucleic acids includes a first synPCCA nucleic acid and a second synPCCA nucleic acid. The first synPCCA nucleic acid may be a forward primer and the second synPCCA nucleic acid may be a reverse primer described herein.
In an aspect of the invention, the collection of synPCCA nucleic acids may include at least one primer and a probe, preferably at least one forward primer, at least one reverse primer, and at least one probe. The probe may comprise any of the synPCCA nucleic acids described herein with respect to other aspects of the invention.
An aspect of the invention provides methods for detecting the expression of synPCCA nucleic acid by cells. These methods may be useful for any of a variety of applications including, for example, any one or more of testing, detecting, quantifying and monitoring the expression of synPCCA polynucleotides by cells after any of the polynucleotide expression cassettes, recombinant expression vectors, rAAVs, or compositions have been administered to the cells. For example, the expression of synPCCA nucleic acid by cells may be tested before administering synPCCA nucleic acid to a subject. If a vector comprising the synPCCA nucleic acid is manufactured, the inventive methods for detecting the expression of synPCCA nucleic acid by cells can be used to measure relative expression of PCCA from the vector. In an aspect of the invention, the method for detecting the expression of synPCCA nucleic acid by cells is carried out by RNA or DNA in situ hybridization.
In an aspect, the method for detecting the expression of synPCCA nucleic acid comprises administering to cells any of the inventive polynucleotide expression cassettes, recombinant expression vectors, rAAVs, or compositions described herein and isolating a sample comprising nucleic acid from the cells that have been administered any of the inventive polynucleotide expression cassettes, recombinant expression vectors, rAAVs, or compositions described herein.
In an aspect of the invention, the method for detecting the expression of synPCCA nucleic acid is carried out prior to administering any of the inventive polynucleotide expression cassettes, recombinant expression vectors, rAAVs, or compositions described herein to a subject.
In an aspect, the method for detecting the expression of synPCCA nucleic acid comprises contacting a sample comprising nucleic acid from cells with any of the inventive synPCCA nucleic acids (primers or probes) or collections of synPCCA nucleic acids (primers or probes) described herein.
The method may comprise extracting nucleic acid from the cells in any suitable manner as is known in the art. The nucleic acid may be RNA and/or DNA. The protocol for extracting nucleic acid may be selected depending on the subject, type of cells in the sample, and nucleic acid to be tested as is known in the art. Preferably, the nucleic acid is extracted in any manner which recovers a testable amount of nucleic acid. The nucleic acid extraction may be carried out using any of a variety of commercially available nucleic acid extraction kits.
The method may comprise contacting the sample of extracted nucleic acid with the synPCCA nucleic acids under conditions which allow the synPCCA nucleic acids to specifically hybridize with the extracted nucleic acid as is known in the art. The method may comprise amplifying the synPCCA nucleic acids and the extracted nucleic acid using any suitable amplification method as is known in the art (e.g., reverse transcription PCR (RT-PCR), or other suitable technique).
The method may further comprise detecting the complex, wherein detection of the complex is indicative of the expression of synPCCA polynucleotide by the cells. Detection of the complex can occur through any number of ways known in the art. In an aspect, the method comprises measuring light emitted from a fluorescent dye using, e.g., a laser. Detecting the complex may, optionally, further comprise measuring the amount of complex formed.
In an aspect of the invention, the method further comprises comparing a presence of the complex in the sample with an absence of complex from a negative sample that lacks synPCCA nucleic acid, wherein detection of the complex is indicative of the expression of synPCCA nucleic acid by the cells.
In an aspect, the inventive methods of detecting the expression of synPCCA nucleic acid by cells may be useful for testing, detecting, quantifying and monitoring the expression of synPCCA polynucleotides by cells of a subject after any of the polynucleotide expression cassettes, recombinant expression vectors, rAAVs, or compositions have been administered to the subject.
In an aspect, the cells are from a subject that has been treated with any of the inventive polynucleotide expression cassettes, recombinant expression vectors, rAAVs, or compositions described herein, and detection of the complex is indicative of the expression of synPCCA nucleic acid by the cells of the subject.
The contacting of the nucleic acid sample from the cells with the synPCCA nucleic acid (or collection of synPCCA nucleic acids) can take place in vitro or in vivo with respect to the subject. Preferably, the contacting is in vitro.
With respect to the inventive methods, the cells may be any type of cells. In an aspect, the cells are heart cells or liver cells. Examples of liver cells include hepatocytes (HCs), hepatic stellate cells (HSCs), Kupffer cells (KCs), and liver sinusoidal endothelial cells (LSECs). Examples of heart cells include cardiomyocytes (CMs), fibroblasts (FBs), endothelial cells (ECs), and peri-vascular cells. In a preferred aspect, the cells are hepatocytes or cardiomyocytes.
When the cells are not cells from a subject, for example, when the method is carried out prior to administering any of the inventive polynucleotide expression cassettes, recombinant expression vectors, rAAVs, or compositions described herein to a subject, the cells may be cells of a cell line. In some aspects, the cells are cells of a heart cell line or a liver cell line. In some preferred aspects, the cells are cells of a hepatocyte cell line or a cardiomyocyte cell line.
In some aspects, the cells are cells of a hepatocyte cell line which does not express one or both of endogenous PCCA mRNA and PCCA protein. For example, the hepatocyte cell line may be a hepatocyte PCCA knock out (KO) cell line (e.g., a HEPG2 PCCA knockout cell line). Cell lines which do not express one or both of endogenous PCCA mRNA and PCCA protein may provide any one or more of a variety of advantages. For example, such cells may make it possible to test, detect, quantify and/or monitor synPCCA nucleic acid expression without possible cellular effects (e.g., a KO cell line may provide little or no background signal that may interfere with the detection of the synPCCA nucleic acid expression).
In another aspect of the invention, the inventive methods of detecting the expression of synPCCA nucleic acid by cells further comprise quantifying the synPCCA nucleic acid expressed by the cells. The synPCCA nucleic acid expressed by the cells may be quantified by any suitable technique known in the art. For example, the quantity of synPCCA nucleic acid expressed by the cells may be compared to a known quantity of expression of a different, reference gene (e.g., Gapdh or beta actin), or the quantity of synPCCA nucleic acid expressed by the cells may be normalized to the quantity of expression of a different, endogenously expressed gene (e.g., Gapdh or beta actin).
In another aspect of the invention, the inventive methods of detecting the expression of synPCCA nucleic acid by cells further comprise quantifying the cells that express the synPCCA nucleic acid. The cells that express the synPCCA nucleic acid may be quantified by any suitable technique known in the art. For example, the quantity of cells expressing synPCCA nucleic acid may be compared to a known quantity of cells expressing a different, reference gene (e.g., Gapdh or beta actin), or the quantity of cells expressing synPCCA nucleic acid may be normalized to the quantity of cells expressing a different, endogenously expressed gene (e.g., Gapdh or beta actin).
As used herein, “determining”, “determination”, “detecting”, or the like are used interchangeably herein and refer to the detecting or quantitation (measurement) of a molecule using any suitable method, including immunohistochemistry, fluorescence, chemiluminescence, radioactive labeling, surface plasmon resonance, surface acoustic waves, mass spectrometry, infrared spectroscopy, Raman spectroscopy, atomic force microscopy, scanning tunneling microscopy, electrochemical detection methods, nuclear magnetic resonance, quantum dots, and the like. “Detecting” and its variations refer to the identification or observation of the presence of a molecule in a biological sample, and/or to the measurement of the molecule's value.
This example demonstrates that synPCCA1 is expressed at a higher level than the wild type human PCCA1 gene in cell culture studies.
Six synthetic codon-optimized human propionyl-CoA carboxylase subunit alpha genes (synPCCA1-6) were engineered using an iterative approach, wherein the naturally occurring PCCA cDNA (NCBI Reference Sequence: NM_000282.4) was optimized codon by codon to create (synPCCA1-6) (SEQ ID NOs: 2-7), using a variety of codon optimization methods, one of which incorporated factors involved in protein expression, such as codon adaptability, mRNA structure, and various cis-elements in transcription and translation. The resulting sequences were manually inspected and subject to expert adjustment. The synPCCA alleles displayed maximal divergence from the PCCA cDNA at the nucleotide level yet retained optimally utilized codons at each position.
To improve the expression of PCC and create a vector that could express the human PCCA gene in a more efficient fashion, synPCCA1 was cloned using restriction endonuclease excision and DNA ligation into an expression vector under the control of the strong chicken R-actin promoter (CBA) (Chandler, et al. 2010 Mol Ther 18:11-6) or the active but not as potent elongation factor 1 alpha promoter (EF1a). The constructs expressing either PCCA or synPCCA1 with the CBA or synPCCA6 with EF1α long or short promoters were then transfected into 293FT cells using Lipofectamine™ (Life Technologies). Cloning and transfection methods are well understood by practitioners of the art (Sambrook, Fritsch, Maniatis. Molecular Cloning: A Laboratory Manual). After 48 hours, cellular protein was extracted from the transfected cells and evaluated for PCC protein expression using Western analysis (Chandler, et al. 2010 Mol Ther 18:11-6). The results show that synPCCA1 is expressed at 140% the level of the wild type human PCCA gene (
This example demonstrates AAV9 gene therapy in Pcca knock-out (Pcca−/−) Mice.
The promising expression data from both constructs led to the production of AAV9-CBA-synPCCA1 which was delivered to neonatal Pcca−/− mice. As presented in
In a similar study, long term survival of neonatal AAV9-CBA-synPCCA1 treated Pcca−/− mice was performed. Untreated Pcca−/− (n=10) mice served as a control and were compared to Pcca−/− mice (n=9) treated with 3×1011 VC of AAV-CBA-synPCCA1 delivered by retroorbital injection at birth. As can be seen in
This example demonstrates the design of vectors expressing synPCCA1.
Next, a series of vectors was designed to express synPCCA1 from the long elongation factor 1 alpha promoter EF1 or EF1AS promoter in combination with a 3′ the HPRE.
This example demonstrates that the vectors of Example 3 are expressed in human cells.
The vectors were studied for expression in human cells.
This example demonstrates the improved survival of Pcca−/− mice treated with AAV9 synPCCA1 vectors as compared to untreated mice.
Next, AAV9 vectors were prepared using methods well known to practitioners (Chandler, et al. 2010 Mol Ther 18:11-6) and used to treat Pcca−/− mice.
Animal studies were reviewed and approved by the National Human Genome Research Institute Animal User Committee. Retroorbital injections were performed on non-anesthetized neonatal mice, typically within several hours after birth. Viral particles were diluted to a total volume of 20 microliters with phosphate-buffered saline immediately before injection and were delivered into the retroorbital plexus using a 32-gauge needle.
Treatment with synPCCA1 polynucleotide delivered using an AAV (adeno-associated virus) rescued the Pcca−/− mice from neonatal lethality (
This example demonstrates the features of mouse models of PA.
Studies were initiated to develop systemic gene therapy as a treatment for PA, with the goal of targeting hepatocytes and cardiomyocytes for transgene expression. As a first step, improved alleles were generated using CRISPR/Cas9 genome editing to engineer mutations that are comparable to those seen in the patients, such as frameshift-stop and missense changes, into Pcca.
Among the mutations recovered, two were further studied: mPCCAp.Q133LfsX41, caused by a 4 bp deletion in the Pcca gene (and also designated Pcca4bp del, Pcca−, and Pcca K), and the missense mutation mPCCAp.A134T. mPCCAp.Q133LfsX41/p.Q133LfsX41 mice, also designated Pcca−/−, are null at the level of PCCA protein expression (cross reactive material, CRM−) and recapitulate the neonatal lethal form of PA in humans, while mPCCAp.A134T/p.A134T and mPCCAp.Q133LfsX41/p.A134T mice are fully viable as adults, yet display markedly reduced PCC activity and mildly elevated levels of 2-methylcitric acid, a metabolic biomarker of PA. Table 3 presents a summary of the mouse models.
This example demonstrates the design of a vector for the delivery of synPCCA (AAV9-EF1s-hPCCA-HPRE Final).
An expression cassette, EF1s-hPCCA-HPRE Final, was developed and improved from the parental vector (Ef1S-synPCCA1-HPRE parent) (
The kanamycin resistant transgene was added, and the product was then scaled for production and packaged with an AAV9 capsid. The AAV9-EF1s-hPCCA-HPRE Final vector was purified by column chromatography and centrifugation. The AAV9-EF1s-hPCCA-HPRE Final vector including the kanamycin resistance gene comprised SEQ ID NO: 42 (Table 6B).
The AAV9-EF1s-hPCCA-HPRE Final vector is an AAV9 vector expressing a functional human codon optimized cDNA encoding PCCA, under control of the EFIS promoter. In humans, endogenous PCCA protein is ubiquitously expressed, therefore the therapeutic transgene cassette was designed with a constitutive promoter to enable wide expression. The AAV9 capsid was selected to further enable hepatic and cardiac transduction.
This example demonstrates the expression of PCCA encoded by the AAV9-EF1s-hPCCA-HPRE Final vector in a human liver (HepG2) PCCA knockout (KO) cell line.
The AAV9-EF1s-hPCCA-HPRE Final vector of Example 7 was tested for activity and expression in a human liver (HepG2) PCCA knock-out cell line (
A deletion mutation in PCCA was engineered in a human hepatocyte derived cell line (HEPG2) to create the PCCA KO cell line, and used to test the in vitro potency of the AAV9-EF1s-hPCCA-HPRE Final vector applied at varying moiety of infections ranging from 5×104 to 1×106. After 48 hours, the infected PCCA KO cells were harvested and lysed, and 25 μg of total cellular protein was subjected to Western analysis using a PCCA polyclonal antibody. Beta-actin was used as a loading control. A dose response with increasing PCCA after exposure to varying doses of AAV9-EF1s-hPCCA-HPRE Final was apparent and approximated the proof-of-concept AAV9 vector (AAV9.CB7.C1.hPCCA1.RBG) of Example 3 that used the CMV enhanced chicken beta actin promoter to drive the expression of synPCCA1 (
This example demonstrates the efficacy and dose response of the AAV9-EF1s-hPCCA-HPRE Final vector in a mouse model of PA.
The AAV9-EF1s-hPCCA-HPRE Final vector of Example 7 was delivered by retroorbital injection to treat the severely affected neonatal lethal PA mice of Table 3 over doses ranging from 8.3e11 vector genomes/kilogram (vg/kg) to 3.3e14 vg/kg. The doses for the experiment shown in
The three higher doses provided rescue from neonatal lethality, and substantially prolonged the life of the mutant mice in a dose response manner. The control Pcca−/− animals (untreated/PBS treated) died shortly after birth as did those dosed with 8.3×1011 vg/kg. The animals dosed at 8.3×1012 vg/kg had a mean survival of ˜41 days, which increased with dose: those in the 8.3×1013 vg/kg cohorts survived for ˜85 days, while animals in the highest dose group of 3.3×1014 vg/kg lived even longer, with a mean survival past 112.5 days.
Animals dosed with the AAV9-EF1s-hPCCA-HPRE Final vector were bled to measure a biomarker response at day 30, and then sacrificed to assess transgene expression and vector biodistribution. On day 30, the weights of the treated Pcca−/− mice were not different than treated control littermates (
AAV9-EF1s-hPCCA-HPRE Final provided effective rescue from neonatal lethality displayed by mPCCAp.Q133LfsX41/p.Q133LfsX41 mice, with survivors manifesting improvements in growth (
The doses for the experiments shown in
This example demonstrates hepatic and cardiac transgene expression in a mouse model of PA after treatment with the AAV9-EF1s-hPCCA-HPRE Final vector.
In the PA patients, the target tissues are the liver and heart, and therefore, the survey was focused on hepatic and cardiac studies in mice treated with the AAV9-EF1s-hPCCA-HPRE Final vector.
Neonatal Pcca−/− mice were treated with the AAV9-EF1s-hPCCA-HPRE Final vector with a dose of 1e11 GC/pup delivered by retro-orbital injection.
Expression of PCCA in liver and heart was measured by Western blot on DOL 30. PCCA expression was detected in the heart and liver of the treated mice (
AAV9-EF1s-hPCCA-HPRE Final treated mPCCAp.Q133LfsX41/p.Q133LfsX41 mice exhibited robust PCCA transgene expression in the liver and heart as measured by Western blotting (
This vector, AAV9-EF1s-hPCCA-HPRE Final, and data obtained from mPCCAp.Q133LfsX41/p.Q133LfsX41 (Pcca−/−) neonatal mouse model experiments establish a new AAV gene therapy for PA caused by PCCA mutations, and further provide first-in-human (FIH) dose ranges for efficacy.
All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
The use of the terms “a” and “an” and “the” and “at least one” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The use of the term “at least one” followed by a list of one or more items (for example, “at least one of A and B”) is to be construed to mean one item selected from the listed items (A or B) or any combination of two or more of the listed items (A and B), unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
This patent application claims the benefit of U.S. Provisional Patent Application No. 63/294,511, filed Dec. 29, 2021, which is incorporated by reference in its entirety herein.
This invention was made with Government support under project number Z01HG200318-14 by the National Institutes of Health, National Human Genome Research Institute. The Government has certain rights in the invention.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2022/082527 | 12/29/2022 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63294511 | Dec 2021 | US |
